2023
Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, PMCID: PMC10751105, DOI: 10.1111/bjh.18899.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCOVID-19 vaccinationAntibody responseCell diseaseSARS-CoV-2 vaccinationIgG immune responseSimilar antibody responsesOptimal vaccination strategyIgG titresIgG responsesVaccination strategiesImmune responseSCD controlsGeneral populationPatientsVaccinationDiseaseResponseCohortTitres
2021
Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease
Madany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson JE, Gibb DR. Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers In Medicine 2021, 8: 679030. PMID: 34368185, PMCID: PMC8339405, DOI: 10.3389/fmed.2021.679030.Peer-Reviewed Original ResearchSickle cell diseaseCOVID-19 severityIFNα/βType 1 interferonCell diseaseSARS-CoV-2 infectionType 1 interferon responseCorona Virus Disease-19 (COVID-19) pandemicCohort of patientsMajority of patientsInterferon gene signatureIFNα/β productionRace-matched controlsDisease-19 pandemicCOVID-19Express elevated levelsMajority of evidenceSCD diseaseSevere sequelaeChronic inflammationFavorable outcomeVariable progressionClinical consequencesGeneral populationPatients